# 바이오스페이스 일일 뉴스 리포트 - 2025년 10월 28일


## 주요 헤드라인

1. **BridgeBio Pops on Late-Stage Limb-Girdle Muscular Dystrophy Data (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/bridgebio-pops-on-late-stage-limb-girdle-muscular-dystrophy-data>

2. **BridgeBio Pops on Late-Stage Limb-Girdle Muscular Dystrophy Data (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/bridgebio-pops-on-late-stage-limb-girdle-muscular-dystrophy-data>

3. **Deep Dive (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/deep-dive-chinese-biotech-innovation-cant-be-stopped>

4. **Deep Dive (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/deep-dive-chinese-biotech-innovation-cant-be-stopped>

5. **Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/intellia-pauses-phase-iii-attr-trials-for-crispr-gene-therapy-after-life-threatening-liver-toxicity>

6. **Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/intellia-pauses-phase-iii-attr-trials-for-crispr-gene-therapy-after-life-threatening-liver-toxicity>

7. **Dyne Primed for Suitors Amid Novartis’ $12B Avidity Acquisition (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/dyne-primed-for-suitors-amid-novartis-12b-avidity-acquisition>


---
*2025년 10월 28일 바이오스페이스 뉴스 피드에서 생성된 리포트*